Geron Company (Nasdaq: GERN), a late-stage medical biopharmaceutical corporate, as of late introduced the appointment of John F. McDonald as an unbiased member of its Board of Administrators, efficient September 7, 2022.
“Along with his 3 many years within the biopharmaceutical business throughout trade building and funding and company technique, John is a extremely revered and seasoned R&D government with treasured pharmaceutical and biotechnology revel in. We enthusiastically welcome him to the Board,” stated John A. Scarlett, M.D., Geron’s Chairman and Leader Govt Officer. “We consider John’s experience will upload business and strategic views in guiding our targets to advance imetelstat in opposition to doable registration and commercialization.”
“I’m thrilled to enroll in Geron’s Board at this thrilling time, as the corporate nears top-line ends up in decrease menace MDS in early January 2023,” stated John F. McDonald. “In my profession, I’ve observed quite a few ways in which firms can strategically evolve their companies, and I stay up for contributing to Geron’s long term enlargement and good fortune as the corporate brings the possibility of illness amendment with imetelstat to sufferers with hematologic malignancies.”
These days, Mr. McDonald serves as Company Vice President, World R&D Trade Building, for Novo Nordisk A/S, the place he leads R&D trade building actions and funding methods, in addition to participates within the advent of study, early building, and healing pipeline diversification and augmentation methods. From 2011 to 2018, Mr. McDonald was once Vice President, Trade Building, at Biogen Inc., the place he led trade building and negotiated a lot of strategic alliances, licenses and acquisitions. From 2006 to 2011, Mr. McDonald served as Managing Director at MPM Capital LP, the place he served as the main trade building and asset technique useful resource for a couple of portfolio firms. Previous to 2006, Mr. McDonald held trade building, company technique, and felony roles of accelerating accountability at more than a few biopharmaceutical firms, together with Millennium Prescribed drugs Inc. (now a Takeda Oncology Corporate), Genzyme Corp (now a part of Sanofi) and Genentech, Inc. (now a member of the Roche Staff). Mr. McDonald holds a J.D. from College of California Hastings School of the Legislation and an M.B.A. and B.S. from the Haas College of Trade, College of California, Berkeley.
Geron is a late-stage medical biopharmaceutical corporate targeted at the building and doable commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Corporate recently is undertaking two Segment 3 medical trials: IMerge in decrease menace myelodysplastic syndromes and IMpactMF in relapsed/refractory myelofibrosis.
Use of Ahead-Having a look Statements
Aside from for the ancient knowledge contained herein, this press unencumber incorporates forward-looking statements made pursuant to the “secure harbor” provisions of the Non-public Securities Litigation Reform Act of 1995. Buyers are cautioned that such statements, come with, with out limitation, the ones relating to: (i) the prospective registration and commercialization of imetelstat; (ii) the expectancy to learn out top-line ends up in decrease menace MDS in early January 2023; (iii) the disease-modifying doable of imetelstat; and (iv) different statements that aren’t ancient information, represent ahead searching statements. Those forward-looking statements contain dangers and uncertainties that may reason precise effects to vary materially from the ones in such forward-looking statements. Those dangers and uncertainties, come with, with out limitation, dangers and uncertainties associated with: (a) whether or not the present or evolving results of the COVID-19 pandemic and/or the Russia/Ukraine war reason world financial and monetary disruptions that materially and adversely affect Geron’s trade and trade potentialities, its monetary situation and the way forward for imetelstat; (b) whether or not Geron overcomes the entire doable delays and different antagonistic affects led to by way of the present or evolving results of the COVID-19 pandemic and/or the Russia/Ukraine war, and overcomes the entire enrollment, medical, protection, efficacy, technical, medical, highbrow belongings, production and regulatory demanding situations with a view to have the monetary assets for, and to satisfy the predicted timeline of early January 2023 for the decrease menace MDS top-line readout; (c) whether or not regulatory government allow the additional building of imetelstat on a well timed foundation, or in any respect, with none medical holds; (d) whether or not any long term efficacy or protection effects would possibly reason the benefit-risk profile of imetelstat to transform unacceptable; (e) whether or not imetelstat in reality demonstrates disease-modifying task in sufferers with hematologic malignancies; and (f) whether or not there are disasters or delays in production or supplying enough amounts of imetelstat or different medical trial fabrics in a well timed method, or in any respect. More information at the above dangers and uncertainties and extra dangers, uncertainties and components that might reason precise effects to vary materially from the ones within the forward-looking statements are contained in Geron’s filings and periodic stories filed with the Securities and Alternate Fee below the heading “Possibility Components” and in different places in such filings and stories, together with Geron’s quarterly record on Shape 10-Q for the quarter ended June 30, 2022 and long term filings and stories by way of Geron. Undue reliance must no longer be put on forward-looking statements, which discuss handiest as of the date they’re made, and the information and assumptions underlying the forward-looking statements would possibly trade. Aside from as required by way of regulation, Geron disclaims any legal responsibility to replace those forward-looking statements to mirror long term knowledge, occasions or cases.